Telix Pharmaceuticals Limited

DB:T3X Stock Report

Market Cap: €3.1b

Telix Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:T3X Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
21 Jul 26Buy€16,574,715JPMorgan Chase & Co.Company1,648,940€10.82
21 Jul 26Sell€13,700,613JPMorgan Chase & Co.Company1,390,847€10.86
17 Jul 26Sell€676JPMorgan Chase & Co.Company74€9.13
13 Jul 26Sell€17,214JP Morgan Asset ManagementCompany1,769€9.73
10 Jul 26Buy€16,848JP Morgan Asset ManagementCompany1,702€9.90
26 Jun 26Buy€11,464,119JPMorgan Chase & Co.Company1,295,296€9.67
25 Jun 26Sell€34,481JP Morgan Asset ManagementCompany3,810€9.51
25 Jun 26Sell€1,784,746JPMorgan Chase & Co.Company188,435€9.69
19 Jun 26Buy€480,281JP Morgan Asset ManagementCompany54,035€8.89
11 Jun 26Buy€83,501David GillIndividual10,200€8.19
03 Jun 26Buy€20,099,033JPMorgan Chase & Co.Company2,256,035€9.69
03 Jun 26Sell€14,606,956JPMorgan Chase & Co.Company1,642,945€9.65
01 Jun 26Buy€599JPMorgan Chase & Co.Company74€8.09
04 May 26Sell€8,151,653Challenger LimitedCompany856,223€9.52
29 Apr 26Buy€608,004Christian BehrenbruchIndividual67,935€8.95
29 Apr 26Buy€852,211Christian BehrenbruchIndividual67,935€12.71
24 Apr 26Buy€2,724,317JPMorgan Chase & Co.Company320,713€9.27
24 Apr 26Sell€1,154,713JPMorgan Chase & Co.Company125,136€9.42
15 Apr 26Buy€16,420JP Morgan Asset ManagementCompany1,816€9.04
14 Apr 26Buy€5,764,792JPMorgan Chase & Co.Company1,326,566€9.65
14 Apr 26Sell€8,125,911JPMorgan Chase & Co.Company2,188,808€9.54
13 Apr 26Sell€434,742Challenger LimitedCompany46,000€9.45
01 Apr 26Sell€10,986,845Challenger LimitedCompany1,385,977€7.93
30 Mar 26Buy€56,118JP Morgan Asset ManagementCompany8,812€6.88
25 Mar 26Sell€17,058JPMorgan Chase & Co.Company2,312€7.92
20 Mar 26Buy€7,788,514Challenger LimitedCompany1,129,501€6.90
19 Mar 26Sell€748,187JP Morgan Asset ManagementCompany100,028€7.61
10 Mar 26Buy€7,751,002Challenger LimitedCompany1,153,900€6.72
05 Mar 26Buy€3,573JPMorgan Chase & Co.Company581€6.15
05 Mar 26Sell€981,355Challenger LimitedCompany158,600€6.19
17 Feb 26Buy€4,505,806JPMorgan Chase & Co.Company846,943€6.15
17 Feb 26Sell€1,542,540JPMorgan Chase & Co.Company267,302€6.21
04 Feb 26Buy€5,981,031JPMorgan Chase & Co.Company904,800€7.04
04 Feb 26Sell€3,940,783JPMorgan Chase & Co.Company591,278€7.03
21 Jan 26Buy€47,672,234Challenger LimitedCompany5,512,680€8.65
21 Jan 26Buy€3,400,209JPMorgan Chase & Co.Company544,347€6.42
21 Jan 26Sell€7,027JPMorgan Chase & Co.Company1,138€6.18
21 Jan 26Sell€55,131,210Challenger LimitedCompany7,345,877€7.51
20 Jan 26Buy€3,106JPMorgan Chase & Co.Company474€6.55
20 Jan 26Buy€21,554,842JPMorgan Chase & Co.Company2,902,453€8.82
20 Jan 26Sell€208,546JP Morgan Asset ManagementCompany30,266€8.20
20 Jan 26Sell€36,204,264JPMorgan Chase & Co.Company4,967,439€8.82
12 Nov 25Buy€95,322,338JPMorgan Chase & Co.Company10,122,238€14.31
12 Nov 25Sell€76,946,444JPMorgan Chase & Co.Company8,175,593€14.31
10 Nov 25Sell€1,892,957JP Morgan Asset ManagementCompany237,822€13.48
23 Sep 25Buy€15,259,533Challenger LimitedCompany1,675,946€9.11
23 Sep 25Sell€877,169Challenger LimitedCompany101,000€8.68
10 Sep 25Sell€3,338,886Challenger LimitedCompany425,000€7.86
09 Sep 25Buy€2,518,423Challenger LimitedCompany318,741€7.90
28 Aug 25Sell€4,013,980Challenger LimitedCompany484,952€8.28
22 Aug 25Buy€2,522,691Challenger LimitedCompany248,014€10.17

Insider Trading Volume

Insider Buying: T3X insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of T3X?
Owner TypeNumber of SharesOwnership Percentage
Private Companies4,817,3951.42%
Public Companies10,947,1813.22%
Individual Insiders50,399,64614.8%
General Public122,404,79036%
Institutions151,215,28244.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 60.25% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.95%
JPMorgan Chase & Co.
30,417,227€273.6m17.8%0.04%
7.04%
State Street Investment Management
23,930,337€215.2m-28.2%0.01%
6.67%
Andreas Kluge
22,675,000€203.9m0%no data
6.41%
Christian Behrenbruch
21,796,941€196.0m0.31%no data
4.98%
Challenger Limited
16,907,315€152.1m-1.14%6.31%
3.35%
Citigroup Inc.
11,391,435€102.5m0.53%0.05%
3.22%
Grand Pharmaceutical Group Limited
10,947,181€98.5m0%no data
2.38%
Vanguard Capital Management, LLC
8,088,252€72.7m12.4%no data
2.26%
Australian Super Pty Ltd
7,687,939€69.1m0%0.05%
1.89%
Norges Bank Investment Management
6,429,128€57.8m0%no data
1.85%
Vanguard Investments Australia Limited
6,287,673€56.5m4.01%0.06%
1.77%
BlackRock, Inc.
6,009,371€54.0m-1.77%no data
1.44%
UV-Cap GmbH & Co KG
4,878,261€43.9m-10.1%no data
1.28%
RBC Global Asset Management Inc.
4,340,294€39.0m-0.44%0.02%
1.07%
Mark Nelson
3,628,750€32.6m0%no data
0.74%
Oncidium Foundation
2,513,616€22.6m0%no data
0.73%
Vanguard Fiduciary Trust Company
2,484,105€22.3m13.3%no data
0.71%
Netwealth Investments Ltd.
2,406,576€21.6m19.7%0.2%
0.58%
Sanlam Investments Uk Limited
1,959,548€17.6m0%0.64%
0.57%
BetaShares Capital Limited
1,953,717€17.6m4.18%0.06%
0.56%
Lightpoint Medical Ltd
1,918,112€17.3m0%no data
0.52%
Yelwac Pty Ltd
1,762,500€15.9m0%no data
0.5%
Dimensional Fund Advisors LP
1,687,274€15.2m-1.12%no data
0.44%
Portland Investment Counsel Inc.
1,497,964€13.5m9.9%4.12%
0.33%
Nancris Pty Ltd
1,136,783€10.2m0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/05 02:39
End of Day Share Price 2026/08/05 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Telix Pharmaceuticals Limited is covered by 23 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Melissa BensonBarrenjoey Markets Pty Limited
John HesterBell Potter
Shane StoreyCanaccord Genuity